Affiliations: [a]
Institute of Organic Chemistry and Biochemistry, AS CR, Prague, Czech Republic
| [b]
Institute of Physiology, AS CR, Prague, Czech Republic
| [c] Université Lille, INSERM, CHU Lille, UMR – S 1172 – Jean Pierre Aubert Research Centre, Alzheimer and Tauopathies, Lille, France
Correspondence:
[*]
Correspondence to: Lenka Maletínská, Institute of Organic Chemistry and Biochemistry, AS CR, Flemingovo namesti 2, Prague 166 10, Czech Republic. Tel.: +420 220 183 567; E-mail: [email protected].
Abstract: Alzheimer’s disease (AD) is one of the most prevalent neurodegenerative diseases, characterized by the accumulation of extracellular amyloid plaques and intraneuronal neurofibrillary tangles. These tangles mainly consist of hyperphosphorylated tau protein. As it induces tau hyperphosphorylation in vitro and in vivo, hypothermia is a useful tool for screening potential neuroprotective compounds that ameliorate tau pathology. In this study, we examined the effect of prolactin-releasing peptide (PrRP), its lipidized analog palm11-PrRP31 and glucagon-like-peptide-1 agonist liraglutide, substances with anorexigenic and antidiabetic properties, on tau phosphorylation and on the main kinases and phosphatases involved in AD development. Our study was conducted in a neuroblastoma cell line SH-SY5Y and rat primary neuronal cultures under normothermic and hypothermic conditions. Hypothermia induced a significant increase in tau phosphorylation at the pThr212 and pSer396/pSer404 epitopes. The palmitoylated analogs liraglutide and palm11-PrRP31 attenuated tau hyperphosphorylation, suggesting their potential use in the treatment of neurodegenerative diseases.
